FDA releases guidance on nonproprietary naming of biologics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA released the final guidance for industry “Nonproprietary Naming of Biological Products.”

The guidance describes the agency’s thinking on the need for biological products previously and newly licensed under the Public Health Service Act (PHS Act) to bear nonproprietary names that include an FDA-designated suffix.

Under this naming convention, FDA will designate a distinguishing suffix that is devoid of meaning and composed of four lowercase letters in the nonproprietary names for originator biological products, related biological products, and biosimilar products. The suffix will be attached to each product’s core name with a hyphen.

FDA is continuing to consider the appropriate suffix format for interchangeable products.

Table of Contents

YOU MAY BE INTERESTED IN

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.” 

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community.  The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login